To identify differentially expressed genes in multiple sclerosis, microarrays were used in a stringent experimental settingleukapheresis from disease-discordant monozygotic twins and gene expression profiling in CD4 + and CD8 + T-cell subsets.
Introduction
Multiple sclerosis is a CNS disease driven by inflammatory and neurodegenerative components (Compston and Coles, 2008) . Its cause is unknown and the underlying pathogenic mechanisms are still poorly understood. As in other complex traits, technologies that allow non-hypothesis-driven investigations through high-throughput screening may increase the chances of detecting alterations with aetiopathogenetic relevance (Martin and Leppert, 2004) . However, due to limitations in their reproducibility, complexities in data analysis and costs, these studies are-in some instances-descriptive and do not fully exploit their potential of being unbiased tools to pick up new clues.
In an attempt to optimize the reproducibility of data from microarrays, we reduced the number of variables by performing gene expression profiling in peripheral blood cells of diseasediscordant monozygotic twins. The co-twin control design provides the best possible matching on a multitude of known and unknown potential confounding factors (MacGregor et al., 2000) , representing an ideal setting for investigating multifactorial diseases and performing high-throughput screenings (Baranzini et al., 2010) . Importantly, in our study the affected twin was free of disease-modifying therapies. To decrease further the number of variables, we avoided the admixture of different peripheral blood mononuclear cell (PBMC) types by separately investigating CD4
+ and CD8 + T-cell subsets. The separate analysis of the two subpopulations allows a direct comparison of their involvement in disease pathogenesis and may disclose new interactions between subsets. In principle, given the increasing number of relevant subpopulations that are being described within the CD4 + and CD8 + T cells, even more discrete phenotypes should be investigated. Nonetheless, it is impractical to perform high-throughput screening on several cellular subsets in parallel. We therefore chose to put gene expression results into context while confirming microarray results with flow cytometry of a larger series of non-twin patients with multiple sclerosis, rheumatoid arthritis and of healthy controls. To this purpose, multicolour analyses were performed ex vivo and in functional in vitro assays. Finally, having found circulating CD8 + T cells with pathogenetic potential, we verified their presence in multiple sclerosis brain immune infiltrates. In this study, microarrays in multiple sclerosis-discordant monozygotic twins and cytofluorimetric experiments in patients with multiple sclerosis, rheumatoid arthritis and in healthy controls all confirmed a multiple sclerosis-related overexpression of killer cell lectin-like receptor subfamily B, member 1, also known as natural killer receptor protein 1a/CD161, on CD8 + peripheral blood
T cells. This gene was presented by the International Multiple
Sclerosis Genetics Consortium as one of the non-MHC candidate loci (Hafler et al., 2007) though it did not reach the suggestive evidence level in a subsequent meta-analysis (De Jager et al., 2009) . Virtually all the CD161 high were chemokine (C-C motif) 
Materials and methods
Patients and healthy donors Table 1 summarizes the characteristics of patients with multiple sclerosis. Gene expression analysis was performed on six pairs of monozygotic twins (mean age 38.33 AE 5.59; female : male ratio 4 : 2), who were discordant (four) and concordant (two) for multiple sclerosis. Cumulatively, 43 patients with relapsing-remitting multiple sclerosis (mean age 37.59 AE 9.98; female : male ratio 26:18), 10 patients with rheumatoid arthritis (mean age 57 AE 13.9; female : male ratio 10 : 0) and 47 healthy donors (mean age 47.4 AE 12; female : male ratio 34 : 13) were included for real-time polymerase chain reaction, flow cytometric analysis and enzyme-linked immunosorbent assay. All affected individuals were treatment naive, except for three who had stopped disease-modifying therapies two years before study enrolment. All the investigations were performed at least 3 months after the last steroid therapy. A contrast-enhanced MRI was obtained from the affected twins and the sporadic patients with multiple sclerosis within 24 h of sampling. The local ethics committee approved the protocol and all patients provided informed consent prior to entering the study. Statistical analysis was performed using Graph Pad Prism 5 for the non-twin patients and healthy donors. Statistical significance is expressed by P-values and was generated using a standard two-tailed unpaired t-test.
Flow cytometry
For polychromatic flow cytometry, aliquots of 0.5 Â 10 6 fresh PBMCs were stained with monoclonal antibodies conjugated with the appropriate fluorochrome at previously defined optimal concentrations. The following antibodies were used: b TCR, CD4, CD8, CD45RA, CD161 and CD56 (Beckman Coulter); CD3, CCR4 and IFN-(BD Biosciences, San Jose, CA, USA); CD27, IL-13, IL-17, IL-18R, IL21 and IL-22 (eBioscience, San Diego, CA, USA); CCR7 (R&D Systems, MN, USA); Perforin and CCR6 (Pharmingen, San Diego, CA, USA); CX(3)CR1 (MBL, Woburn, MA, USA); IL-2 (BioLegend, San Diego, CA, USA). For intracellular staining, freshly isolated PBMCs were stimulated with plate bound anti-CD3 purified monoclonal antibody (5 mg/ml; Pharmingen, San Diego, CA, USA) alone or together with 10 or 20 mg/ml of purified antiCD161 (clone DX12, BD Biosciences) or Ig isotype control, in the presence of IL-2 (20 U/ml, Roche Diagnostic) and brefeldin A (10 mM; Sigma-Aldrich, St Louis, MO, USA). After 6 h of stimulation, cells were stained following standard procedures with anti-b TCR, anti-CD8 and anti-IFN-antibodies. For intracellular cytokine stainings, cells were stimulated with phorbol myristate acetate and ionomycin at 1 mg/ml (Sigma-Aldrich). For proliferation assay, freshly isolated PBMCs were labelled with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), (Invitrogen, Eugene, OR, USA) following standard protocols and stimulated with or without 20 ng/ml IL-12 (Pharmingen). After 48 h IL-2 was added (20 U/ml) to all samples and on Day 5 the cells were labelled and analysed by flow cytometry on a CyAn (Beckman Coulter) or on a fluorescence activated cell sorting Canto (Becton Dickinson). Data were compensated and analysed using FlowJo software (TreeStar, Ashland, OR, USA). Statistical analysis was performed using Graph Pad Prism 5. Statistical significance is expressed by P-values and was generated using a standard two-tailed unpaired t-test.
Enzyme-linked immunosorbent assay CD8 + T lymphocytes were sorted from freshly isolated PBMCs based on CD161 expression, using a MoFlo (Beckman Coulter). Sorted CD161 high CD8 + , CD161 low CD8 + and CD161 À CD8 + cell subsets were stimulated for 24 h at 37 C with antiCD3 and antiCD28-coated Dynabeads Õ (Invitrogen), with or without 20 ng/ml IL-12 (Pharmingen). Supernatants were harvested and the presence of IFN-was determined by a standard two-site sandwich enzyme-linked immunosorbent assay. Antibodies for IFN-were purchased from Endogen. Enhanced protein-binding enzyme-linked immunosorbent assay plates (Nunc Maxisorb; Nunc Maxi Corp., Roskilde, Denmark) were used.
Immunofluorescence analysis of postmortem multiple sclerosis brain tissue Snap-frozen brain tissue blocks from four patients with secondary progressive multiple sclerosis and one control subject who died from cardiac failure were analysed. Tissues were provided by the UK Multiple Sclerosis Tissue Bank at Imperial College, London. A snap-frozen tonsil was used as positive control. Multiple sclerosis lesions were analysed and classified by histopathological methods, i.e. haematoxylin/eosin staining and Oil Red O, and the combined Luxol fast blue-periodic acid-Schiff reaction to estimate myelin breakdown and phagocytosis. For the multiple sclerosis cases, four cerebral tissue blocks containing areas of white matter demyelination (classified as chronic active lesions) and intact meninges were examined.
For triple immunofluorescence stainings, cryosections from tonsil and multiple sclerosis brain tissues were fixed in acetone for 10 min and stained using the following purified antibodies: anti-CD161 (natural killer receptor protein 1a) mAb (clone DX12, BD Biosciences), anti-CD8 rabbit polyclonal Ab (Affinity Bioreagent), and anti-CD3 (Santa Cruz Biotechnology) or anti-human IFN-(AbD Serotec, Oxford, UK) goat polyclonal antibodies diluted in phosphate buffered saline containing 2% bovine serum albumin. After an overnight incubation, sections were washed and treated with TRITC-conjugated donkey anti-rabbit IgG, fluorescein-conjugated donkey anti-mouse IgG and AMCA-conjugated donkey anti-goat IgG (Jackson Immunoresearch Laboratories, Cambridgeshire, UK) diluted in phosphate buffered saline containing 5% normal donkey serum (Jackson Lab.) for 1 h, washed again in phosphate buffered saline and sealed in the aqueous mounting medium Vectashield Õ (Vector Laboratories, Burlingame, CA, USA). For negative controls, the primary antibodies were replaced with pre-immune sera and IgG isotype control. Slides were viewed and analysed under epifluorescence with a Zeiss Axiophot microscope equipped with an Axiocam digital camera; images were acquired using the Axiovision 4 AC software.
Results

Gene expression analysis: microarray and real-time polymerase chain reaction
Microarray analysis was performed on four pairs of monozygotic twins discordant for multiple sclerosis. The gene expression profiles of peripheral blood CD4 + and CD8 + T cells were similar between each pair of twins and no transcript proved to be disease associated in all four twin pairs. We therefore chose to validate any trend that could be confirmed in at least three twin pairs. In spite of this relatively loose criterion, no gene was found to be differentially expressed between affected and healthy co-twins in CD4 + T cells, whereas in CD8 + T lymphocytes, interleukin 1 beta (IL-1B), interleukin 8 (IL-8), chemokine (C-C motif) ligand 3 and chemokine (C-C motif) ligand 4 genes were downregulated, and CD161 upregulated, in the affected co-twins. All these differences were validated by real-time polymerase chain reaction (Tables 2 and 3 ). As evident from real-time polymerase chain reactions repeated on samples obtained from three twin pairs at least 48 months apart from the first time-point, the upregulation of CD161 persisted over time; in two concordant twin pairs, CD161 expression did not differ (Table 3) .
Real-time polymerase chain reaction on CD161 transcript was also performed in 20 non-twin patients (mean age 39.45 AE 8.62; female : male ratio 17 : 3) and 18 healthy donors (mean age 40.59 AE 7.77; female : male ratio 14 : 4). The results confirmed the upregulation of the transcript in individuals with multiple sclerosis (2-fold change; P 5 0.05; Supplementary Fig. 1 ).
CD161 expression on CD8 + T cells in multiple sclerosis
To confirm the upregulation of CD161 expression at the protein level and in a larger series, flow cytometric analysis was performed on CD4 + and CD8 + T cells from the peripheral blood of 20 patients with relapse-remitting multiple sclerosis and 47 healthy donors. Ten patients with rheumatoid arthritis were also included in our analysis to evaluate the specificity of the results obtained from patients with multiple sclerosis against another autoimmune disease. The fraction of CD161 + cells in the total CD8 + T-cell population was higher in patients with multiple sclerosis (mean AE SD: 23.97 AE 9.8) compared to healthy donors (mean AE SD: 17.91 AE 8.8; P = 0.03). No significant difference was found between patients with multiple sclerosis and rheumatoid arthritis (mean AE SD: 21.58 AE 7.8), or between patients with rheumatoid arthritis and healthy donors (Fig. 1A) . Furthermore, the expression of CD161 (quantified as median fluorescence intensity) on the surface of CD8 + T cells was higher in patients with multiple sclerosis (mean AE SD: 385.7 AE 122.4) than in healthy Interleukin 8 2.1 1.2 1.0 2.2 CCL3 Chemokine (C-C motif) ligand 3 1.6 8.0 1.1 1.6 CCL4 Chemokine (C-C motif) ligand 4 1.6 1.6 3.6 1.0 CD161 + CD8 + T cells in multiple sclerosis
Brain 2011: 134; 542-554 | 545 donors (mean AE SD: 221.8 AE 180.9; P = 0.002) and in patients with rheumatoid arthritis (mean AE SD: 57.14 AE 39.6; P = 0.0001) (Fig. 1B) , as well as in healthy donors compared with patients with rheumatoid arthritis (P = 0.004). In agreement with the microarray results, the percentage of CD161 + CD4 + T cells and the expression of CD161 on CD4 + T cells were similar in the three groups ( Fig. 1C and D) . Based on levels of CD161 expression, CD8 + cells can be divided into CD161 high and CD161 low . Since it is known that CD161 expression levels define cell subsets with distinct functional properties (Takahashi et al., 2006) we asked whether the increased staining intensity for CD161 was due to the selective expansion of the CD161 high subset. Indeed, as shown in Fig. 1E , patients displayed a significantly higher percentage of CD161 high CD8 + T cells, compared to healthy individuals and to patients with rheumatoid arthritis (P = 0.003 and 0.0009, respectively); CD161 low CD8 + T cells were higher in patients with rheumatoid arthritis than in healthy donors and patients with multiple sclerosis while no difference was observed between the three groups for CD161 À CD8 + T cells.
In order to investigate possible correlations between the circulating CD161 + CD8 + subset and demographic or clinical variables, we enrolled a second group of 23 patients with multiple (Fig. 2) . When we re-analysed the frequency of CD161 + CD8 + T cells in this larger sample of patients with multiple sclerosis we were able to confirm a significant difference between patients with multiple sclerosis and healthy donors ( Supplementary Fig. 2 ). and the IL-18 receptor. The above functional characterization was comparable between patients and healthy donors ( Fig. 3 and Supplementary Fig. 3 ). We then studied the ability to produce Th1-, Th2-and Th17-like cytokines by CD8 + T cells in patients with multiple sclerosis and healthy donors (Fig. 4) . CD161 + CD8 + T cells produced detectable levels of intracellular IFN-after stimulation with anti-CD3. Moreover, the combined stimulation of CD3 and CD161 induced higher IFN-levels compared to ligation of CD3 alone, suggesting a co-stimulatory role of CD161 for IFN-production; in contrast, ligation of CD161 alone did not trigger IFNproduction (Fig. 4A) . Given the known effect of IL-12 in promoting helper 1 profiles (and in particular IFN-production), as well as our previous studies on IL-12-mediated upregulation of CD161 (Poggi et al., 1997 (Poggi et al., , 1998 (Poggi et al., , 1999 , we stimulated sorted CD161 high CD8 + , CD161 low CD8 + and CD161 À CD8 + T cell subsets with a combination of anti-CD3 plus anti-CD28, with or without IL-12 ( Fig. 4B ): IL-12 induced an increase of IFN-release by all three subsets both in patients with multiple sclerosis and in healthy donors, without significant differences; however, the salient effect was a more than 10-fold increase on the CD161 high CD8 + subset (multiple sclerosis, P = 0, 04; healthy donors, P = 0.03). A small but measurable fraction of CD8 + T cells produced IL-17. Notably, the CD161 + subset contained virtually all IL-17 + CD8 + T cells ( Fig. 4C and Supplementary   Fig. 4 ). IL-21 production was confined to the CD161 low and CD161 À , while IL-2 and IL-13 production could be detected mainly in CD161 À lymphocytes. A small fraction of CD8 + cells produced IL-22 regardless of CD161 expression levels. In general, cytokine production did not differ between patients with multiple sclerosis and healthy donors. We also evaluated the effects of IL-12 on the proliferation of CD161 + CD8 + T cells. The stimulation of PBMC with IL-2 in the presence or absence of IL-12 is shown in Fig. 5A . Proliferation was confined to the CD161 high CD8 + T-cell subset in both patients with multiple sclerosis and healthy donors. As expected, culture with IL-12 determined a significant increase in the fraction of CD161 + in the CD8 + T-cell compartment (Fig. 5B) .
Detection of CD161 + CD8 + T cells in the multiple sclerosis brain
We next investigated whether CD161 + CD8 + T cells can migrate into the multiple sclerosis brain. To track CD161 + CD8 + T cells in brain inflammatory infiltrates, we performed triple immunofluorescence stainings with anti-CD161, anti-CD8 and anti-CD3 antibodies in sections of post-mortem multiple sclerosis brain. We analysed brain samples from four cases with secondary progressive multiple sclerosis that contained chronic active white matter lesions and inflamed meninges. Ectopic B-cell follicles (Serafini et al., 2004; Magliozzi et al., 2007) were identified in the meninges of two cases. As previously reported (Friese and Fugger, 2009) , a large proportion (550%) of the CD3 + T cells infiltrating the multiple sclerosis brain were CD8 + . Some triple-positive CD161 + CD8 + CD3 + cells were found in the perivascular cuffs of active (n = 2) and chronic active (n = 4) white matter lesions (Fig. 6A) , representing between $8 and 12% of the CD3 + CD8 + T-cell population. Some CD161 + CD8 + CD3 + cells
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were also identified in meningeal inflammatory infiltrates (data not shown) and inside ectopic B-cell follicles (41% of the CD8 + CD3 + T-cell population) (Fig. 6B) . No CD161, CD8 or CD3 immunoreactivity was detected in sections of non-pathological brain and no triple-positive CD161 + CD8 + CD3 + cells were detected in tonsils (data not shown). This finding is in agreement with the notion that the CD161 + CD8 + CD3 + T-cell subset mainly contains cells with an effector memory phenotype (Takahashi et al., 2006) that would be expected to circulate in the peripheral blood and enter inflamed organs (such as the brain in multiple sclerosis), but not secondary lymphoid organs. Using triple immunofluorescence staining we observed that virtually all CD161 + CD8 + T cells in the three multiple sclerosis brains analysed were immunoreactive for IFN-, thereby confirming their ability to perform effector functions in the target tissue ( Fig. 6C and D) .
Discussion
By combining transcriptome analysis in multiple sclerosisdiscordant monozygotic twins, flow cytometric studies in patients with multiple sclerosis and healthy donor controls, and Concerning the findings that pertain to multiple sclerosis, our data are in agreement with recent work on peripheral blood CD4 + T cells in multiple sclerosis-discordant monozygotic twins, where no difference was found in the messenger RNA transcriptome between healthy and affected co-twins (Baranzini et al., 2010) . However, having included also the CD8 + subset of T cells, the present study adds to the increasing appreciation of the role of CD8 + T cells as effectors of the pathological immune response in multiple sclerosis (Friese and Fugger, 2009 ).
The International Multiple Sclerosis Genetics Consortium has reported an association between CD161 genetic variants and the diseases (Hafler et al., 2007) . The association of this locus with multiple sclerosis was not strong enough to reach the suggestive evidence level in a successive meta-analysis (De Jager et al., 2009) . Independently of the significance of the genetic data, it is intriguing that we could detect differences in CD161 expression also in monozygotic twins, suggesting that the alteration affects multiple sclerosis risk irrespective of its heritable or non-heritable origin. It will be of the utmost interest to verify whether and how genetic (if any) and environmental factors that affect CD161 expression interact and reciprocally amplify their impact on multiple sclerosis pathogenesis. A Figure 4 Continued.
contribute to multiple sclerosis immunopathology through the production of proinflammatory cytokines (Takahashi et al., 2006) . Consistent with these and previous findings (Aldemir et al., 2005) , and supporting the relevance of this subset for multiple sclerosis pathogenesis, we show that CD161 co-stimulates IFNproduction in CD8 + T cells, with the CD161 high CD8 + subset poised to secrete proinflammatory cytokines and to proliferate in the presence of IL-12. Further supporting its co-stimulatory role for T cells, CD161 has recently been reported to act as a ligand for proliferation-induced lymphocyte-associated receptor [PILAR Arrows indicate triple positive cells. Scale bars = 10 mm.
CD8 + T cells (Serafini et al., 2006) . Potential target antigens include myelin autoantigens (Crawford et al., 2004) and/or viral determinants (Tsunoda et al., 2005) . In view of the association between Epstein-Barr virus infection and multiple sclerosis (Ascherio and Munger, 2007) , it is interesting that peripheral CD161 + CD8 + T cells in the Epstein-Barr virus-specific repertoire increase during the latent/reactivating phase of infection (Poon et al., 2005) . Indeed, a dysregulated CD8 + T-cell response to Epstein-Barr virus has been recently reported in multiple sclerosis (Jilek et al., 2008; Pender et al., 2009) , though the presence of Epstein-Barr virus-infected B cells and plasma cells in multiple sclerosis brains remains controversial Peferoen et al., 2009; Pender, 2009; Willis et al., 2009) . In other chronic viral infections such as hepatitis C, CD161 expression is increased on virus-specific CD8 + T cells and, further supporting the migratory capacity of these lymphocytes, is greatest on intrahepatic hepatitis C virus-specific T cells (Northfield et al., 2008; Billerbeck et al., 2010) . A recent study by Turtle et al. (2009) (Gillett et al., 2010) . At variance with the data in multiple sclerosis, we found that CD161 low CD8 + T lymphocytes prevail in rheumatoid arthritis, a result that may be in agreement with observations on a decreased number of circulating CD161 + CD8 + T cells in rheumatic diseases (Mitsuo et al., 2006) . The reasons for this difference between multiple sclerosis and rheumatoid arthritis are, at present, unclear and need further investigation, possibly in studies that also include patients with other autoimmune diseases. IL-17-producing CD8 + T cells are less frequent than the CD4 + Th17 and are confined to the CD27 À CD45RA À CCR6 + subset (Kondo et al., 2009) . In agreement with a very recent report (Billerbeck et al., 2010) , we now show a relationship between CD161 expression and production of IL-17 in the CD8 + T cell subset, mirroring recent results obtained in CD4 + T cells (Cosmi et al., 2008; Kleinschek et al., 2009) . Th17 cells are key inducers of inflammation and autoimmunity (Bettelli et al., 2008; Steinman, 2008) . Looking again at the relevance of the CD161 high CCR6 + CD8 + phenotype from a multiple sclerosis perspective, this finding appears to converge with the demonstration of IL-17 + CD8 + T cells in multiple sclerosis brain lesions (Tzartos et al., 2008; Kebir et al., 2009) , and with evidence that CCR6 + Th17 cells are required for the initiation of experimental autoimmune encephalomyelitis (Reboldi et al., 2009) . The relevance of CD161 high CCR6 + CD8 + T cells with pro-inflammatory cytokine profiles for multiple sclerosis pathogenesis is also supported by a parallel study (Muraro P., personal communication) that shows near disappearance of the same T-cell subset after autologous haematopoietic stem cell transplantation and amelioration of clinical course in patients with multiple sclerosis.
In summary, our work shows that CD161 expression on CD8 + T cells marks a subset of non-cytotoxic, proinflammatory, CCR6 + T lymphocytes that may play a role in multiple sclerosis immunopathogenesis by acting as effectors and targeting the CNS. They also contribute to the ongoing characterization of CD161 expressing T cells.
